News from merrimack pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jan 19, 2016, 18:58 ET

Updated Data Shows ONIVYDE® (irinotecan liposome injection) Combination Regimen Increased One Year Survival by 63% in Patients with Metastatic Pancreatic Cancer

 Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that an updated overall survival analysis of the Phase 3 NAPOLI-1 study of...

Jan 11, 2016, 08:00 ET
Jan 05, 2016, 08:00 ET

Merrimack to Present at the 34th Annual J.P. Morgan Healthcare Conference

 Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Robert Mulroy, President and CEO, is scheduled to present at the 34th...

Dec 22, 2015, 16:16 ET

Merrimack Amends MM-121 Phase 2 Clinical Study in Heregulin-Positive Non-Small Cell Lung Cancer to Support Potential Registration

CAMBRIDGE, Mass., Dec. 22, 2015 /PR Newswire/ – Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced it filed an amendment to its...

Dec 22, 2015, 16:15 ET

Merrimack Announces Private Placement of $175 Million of Senior Secured Notes

 Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) announced today the closing of a private placement of $175 million in aggregate principal...

Dec 04, 2015, 08:00 ET

Merrimack Announces Presentations at the 2015 San Antonio Breast Cancer Symposium

 Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that it will present on its innovative nanoliposomal platform for patients with...

Nov 23, 2015, 08:00 ET

Merrimack and Baxalta Announce Publication of the ONIVYDE™ (irinotecan liposome injection) NAPOLI-1 Study in The Lancet

 Merrimack (Nasdaq: MACK) and Baxalta Incorporated (NYSE: BXLT) today jointly announced that The Lancet has published the article...

Nov 09, 2015, 16:02 ET

Merrimack Reports Third Quarter 2015 Financial Results

 Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a biopharmaceutical company that applies systems biology to develop cancer treatments and...

Oct 27, 2015, 08:00 ET

Merrimack and Baxalta Announce Enrollment of First Patient in Phase 2 Study of ONIVYDE™ (irinotecan liposome injection) in Previously Untreated Front-line Metastatic Pancreatic Cancer

Merrimack (Nasdaq: MACK) and Baxalta Incorporated (NYSE: BXLT) today jointly announced the enrollment of the first patient in an exploratory Phase...

Oct 22, 2015, 13:11 ET

Merrimack Announces U.S. FDA Approval of ONIVYDE™ (irinotecan liposome injection) for the Treatment of Patients with Metastatic Pancreatic Cancer

  Merrimack (Nasdaq: MACK) today announced that ONIVYDE™ (irinotecan liposome injection) has been approved by the U.S. Food and Drug...

Aug 10, 2015, 16:01 ET

Merrimack Pharmaceuticals Reports Second Quarter 2015 Financial Results

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a biopharmaceutical company discovering, developing and preparing to commercialize innovative...

Aug 06, 2015, 08:00 ET

Merrimack Pharmaceuticals Names Dr. Yasir Al-Wakeel as Chief Financial Officer and Head of Corporate Development

 Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that Yasir Al-Wakeel, MA, BM BCh will be appointed Chief Financial Officer and...

Aug 03, 2015, 08:00 ET

Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its Second Quarter 2015 Investor Conference Call and...

Jun 25, 2015, 07:00 ET

U.S. FDA Grants Priority Review for MM-398 New Drug Application

 Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) and Baxalta Incorporated, a wholly-owned subsidiary of Baxter International Inc (NYSE: BAX),...

Jun 15, 2015, 16:01 ET
John M. Dineen

Merrimack Pharmaceuticals Announces the Addition of John M. Dineen, Former CEO of GE Healthcare, to Its Board of Directors

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced the election of John M. Dineen to its Board of Directors. Dineen, the...

Jun 11, 2015, 17:00 ET

Merrimack Pharmaceuticals Announces Expansion of MM-398 (nal-IRI) Imaging Study to Patients with Metastatic Breast Cancer

 Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced the initiation of clinical imaging assessing the use of a potential marker...

Jun 01, 2015, 16:12 ET

Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma

 Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced data for MM-398 (irinotecan liposome injection), also known as...

May 14, 2015, 08:00 ET

Merrimack Pharmaceuticals Announces Presentations at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that data supporting further research and clinical development of MM-398 will...

May 07, 2015, 16:01 ET

Merrimack Pharmaceuticals Reports First Quarter 2015 Financial Results

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a biopharmaceutical company discovering, developing and preparing to commercialize innovative...

May 05, 2015, 08:00 ET

Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced the initiation of a randomized, double-blinded, placebo-controlled Phase 2...